Strategies for combination therapy in oncology: Part two – Working with the “status quo”
This is the second article in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Price and access decisions are critical for maximizing the lifecycle value of an asset or franchise. Life sciences companies seeking to develop successful pricing and access strategies must navigate the complex and evolving interactions between customers and products, and must ensure that their decisions balance strategic and financial goals while enabling appropriate access and reimbursement to medical providers, patients, and caregivers.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comThis is the second article in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In...
It is difficult to imagine someone who hasn’t called on antibiotics to help them through an infection or protect them during a surgery. Thanks to developments...